by Jones Day's PTAB Team | Nov 11, 2016 | Final Written Decisions, Pharmaceutical
By Irina Britva, Ph.D. and Cary Miller, Ph.D. On November 3, 2016, the PTAB issued a Final Written Decision upholding a Horizon Therapeutics LLC (“Horizon”) patent, U.S. 8,642,012 (the ’012 patent), relating to use of Ravicti® (glycerol phenylbutyrate) for treating...
by Jones Day's PTAB Team | Nov 3, 2016 | Pharmaceutical, Trial Institution
By: Irina Britva and Patrick Elsevier On October 17, 2016, the PTAB declined the requests of Swiss Pharma International AG (“Swiss Pharma”) in cases IPR2016-00912, IPR2016-00915, and IPR2016-00916 to institute inter partes reviews (“IPRs”) of three patents owned by...
by Jones Day's PTAB Team | Oct 28, 2016 | Pharmaceutical
By J. Jason Williams and J. Patrick Elsevier, Ph.D. In an October 5, 2016, Final Written Decision, the PTAB denied Coalition For Affordable Drugs II LLC’s (“CFAD’s”) request to invalidate a patent held by Cosmo Technologies Ltd. (“Cosmo”) that covers its commercial...
by Jones Day's PTAB Team | Oct 28, 2016 | Pharmaceutical
By Wanli Tang, Ph.D. and J. Patrick Elsevier, Ph.D. On October 21, 2016, the PTAB issued two final written decisions in cases IPR2015-00990 and IPR2015-01093, invalidating claims 1-27, 31-40, 44-52 and 61-75 of U.S. Patent 7,056,886. These decisions mark the first...
